AIA
BMRN icon

Avalon Investment & Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

Avalon Investment & Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,621
Closed -$428K – 335
2020
Q3 		$428K Buy
5,621
+1,106
+24% +$112K 0.01% 275
2020
Q2 		$557K Buy
+4,515
New +$449K 0.01% 237

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Avalon Investment & Advisory's BMRN Position: Q4 2020 in Review

Avalon Investment & Advisory sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 5,621 shares — an estimated $428K sold.

Avalon Investment & Advisory first reported a position in BMRN in Q2 2020 and held it in 2 quarters. The position peaked at $557K in Q2 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Avalon Investment & Advisory reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Avalon Investment & Advisory sold 5,621 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $428K.
  • Avalon Investment & Advisory first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Avalon Investment & Advisory's BioMarin Pharmaceuticals position peaked at $557K in Q2 2020.
  • 537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Avalon Investment & Advisory's 13F filing for Q4 2020, filed 8 Feb 2021.